Hyperlipidemia is a chronic disorder that plays an important role in the development of\ncardiovascular diseases, type II diabetes, atherosclerosis, hypertension, and non-alcoholic fatty liver\ndisease. Hyperlipidemias have created a worldwide health crisis and impose a substantial burden\nnot only on personal health but also on societies and economies. Transcription factors in the sterol\nregulatory element binding protein (SREBP) family are key regulators of the lipogenic genes in the\nliver. SREBPs regulate lipid homeostasis by controlling the expression of a range of enzymes required\nfor the synthesis of endogenous cholesterol, fatty acids, triacylglycerol, and phospholipids. Thereby,\nSREBPs have been considered as targets for the treatment of metabolic diseases. The aim of this study\nwas to investigate the beneficial functions and the possible underlying molecular mechanisms of\nSREBP decoy ODN, which is a novel inhibitor of SREBPs, in high-fat diet (HFD)-fed hyperlipidemic\nmice. ............................
Loading....